Successful Treatment of SAM Syndrome With Secukinumab Monotherapy: A Case Report of a 16-Month-Old Infant.
Qiaoyu CaoJia HouChaolan PanLi ZhangDaian ChengXiaochuan WangQian LiuPublished in: Dermatitis : contact, atopic, occupational, drug (2023)
Severe dermatitis, multiple allergies, and metabolic wasting (SAM) syndrome is a rare congenital skin disease. We report on a 16-month-old infant presenting with severe disseminated dermatitis, characterized by erythema and lichenified plaques. The crucial result of de novo missense mutation in the DSP gene (c.1769T>C, p.F590S) discovered by next-generation sequencing finally confirmed the diagnosis of SAM syndrome. The eruptions and skin pruritus significantly improved after a 4-week treatment with secukinumab.
Keyphrases
- case report
- ankylosing spondylitis
- copy number
- early onset
- soft tissue
- atopic dermatitis
- randomized controlled trial
- combination therapy
- gene expression
- dna methylation
- autism spectrum disorder
- open label
- genome wide
- rheumatoid arthritis
- drug induced
- replacement therapy
- smoking cessation
- transcription factor
- circulating tumor
- disease activity